A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study-Reference-Cited by-同舟云学术

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study

Published:2012-03 Issue:3 Volume:124 Page:569-574
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Garcia Agustin A.,Sill Michael W.,Lankes Heather A.,Godwin Andrew K.,Mannel Robert S.,Armstrong Deborah K.,Carolla Robert L.,Liepman Marcia K.,Spirtos Nick M.,Fischer Edgar G.,Leslie Kimberly K.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference33 articles.

1. Cancer statistics;Jemal;CA Cancer J Clin,2010

2. Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease;Harries;Lancet Oncol,2002

3. Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells;Alper;Int J Cancer,2000

4. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells;Alper;J Natl Cancer Inst,2001

5. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer;Campiglio;J Cell Biochem,1999

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Target prediction and potential application of dihydroartemisinin on hepatocarcinoma treatment;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-05-07

2. Target prediction and potential application of dihydroartemisin on hepatocarcinoma;2024-04-22

3. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer;Scientific Reports;2024-04-05

4. Ovarian cancer relies on the PDGFRβ–fibronectin axis for tumorsphere formation and metastatic spread;Molecular Oncology;2023-12

5. Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies;Molecular Therapy - Oncolytics;2023-03